论文部分内容阅读
采用单克隆抗体，经流式细胞术测定了５３例脑梗塞患者周围血中血小板活化分子标记物颗粒膜蛋白（ＧＭＰ）ＣＤ６２Ｐ和ＣＤ６３。结果脑梗塞患者的两种ＧＭＰ检出率均显著高于健康对照组（Ｐ＜０．００１）．腔隙性梗塞与大面积梗塞组发病３天以内者的ＣＤ６２Ｐ和ＣＤ６３检出率较发病４～１０天、１１～３０天和３１天以上者为高（Ｐ＜０．０５～０．０２）．但后三组仍高于对照组（Ｐ＜０．０１）。表明脑梗塞患者的血小板活化程度明显增高，甚至在脑梗塞恢复期，其血小板亦处于高活化状态，提示探索能阻止或抑制血小板活化的药物和疗法将是预防和治疗脑梗塞的重要手段之一。
Monoclonal antibodies were used to determine the expression of platelet-activating granule membrane protein (GMP) CD62P and CD63 in peripheral blood of 53 patients with cerebral infarction by flow cytometry. Results The detection rates of two GMPs in patients with cerebral infarction were significantly higher than those in healthy controls (P <0.001). The detection rates of CD62P and CD63 in patients with lacunar infarction and large-area infarction group were higher than those with onset of 4-10 days, 11-30 days and more than 31 days (P <0.05-0.02) . However, the latter three groups were still higher than the control group (P <0.01). Indicating that patients with cerebral infarction platelet activation was significantly higher, and even in the recovery of cerebral infarction, its platelet is also in a high activation state, suggesting that to explore and prevent or inhibit platelet activation drugs and therapies will be an important means of prevention and treatment of cerebral infarction .